World’s First Zero-Off-Target Base-edited NK Cell Therapy Receives IND Approval in Both China and the U.S. The world’s first zero-off-target base-edited NK cell product has received IND approvals from both the U.S. FDA and China’s NMPA.

Base Editing Market Research Report 2023 - Global Forecasts to 2028: Innovative Molecules Engineered to Tackle Rare Genetic Disorders at the Fore-font of Developments Dublin, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The "Global Base Editing Market by Product (Platform, Reagents & Kits, Plasmids), Service (gRNA Design, Cell Line Engineering), Type, Targeted Base...

Exavir Therapeutics announces preclinical data demonstrating complete elimination of HIV from human cells with LNP-delivered Tat-targeted CRISPR-Cas9 Early candidate from XVIR-TAT series demonstrated genetic elimination of HIV and robust anti-retroviral activity with CRISPR-Cas9 based excision Exavir lipid nanoparticles (LNPs) with mRNA...

The Boston Globe Names Beam Therapeutics a Top Place to Work for 2020 CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today has been named...

Beam Therapeutics Announces Key R&D Appointments CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced key...